From November 14 to 17, the 19th Academic Congress of the Chinese Society for Radiation Oncology (CSTRO) was grandly held in Beijing. Neuboron participated in the exhibition with its comprehensive BNCT solution, including the independently developed accelerator-based BNCT treatment system - NeuPEX Block-I, the dedicated treatment planning software - NeuMANTA, and the domestically made integrated diagnosis-treatment boron drugs (therapeutic drug BPA and companion diagnostic drug 18F-BPA). The solution attracted many clinical experts and scholars to stop by for visits and exchanges.
In April this year, Neuboron's NeuPEX system and domestically made boron drugs obtained China's first registered clinical trial approval. Xiamen Humanity Hospital officially launched the drug-device combined registered clinical trial, making it the first project of its kind to enter registered clinical trials in China. After completing subsequent clinical trials and obtaining marketing authorization, Neuboron will provide hospital users with the world-leading new BNCT cancer treatment technology. It will offer both accelerator-based BNCT system medical devices and boron drug products, providing new treatment options for cancer patients and opening a new chapter in China's precision cancer treatment.
Since the commissioning and beam delivery of the NeuPEX system, it has operated stably with continuous beam supply for more than 3 years. During this period, it has successfully completed multi-species and multi-batch animal irradiation experiments (covering cells, mice, rats, and beagles), and carried out over 40 human clinical trial treatments. In addition, Neuboron has collaborated with or undertaken research needs from top domestic and foreign universities and institutions, conducting irradiation experiments for BNCT radiation biology, new drug research, and related projects. These efforts have fully verified the product's stability and reliability, as well as the efficiency and professionalism of the technical and clinical teams from Neuboron and Xiamen Humanity Hospital.
Currently, with the vigorous development of China's BNCT technology, the domestic clinical and academic circles are paying increasing attention to this revolutionary radiotherapy technology. The CSTRO Congress has set up a neutron academic session for three consecutive years, bringing together experts and scholars in China's BNCT clinical research, new drug development, and interdisciplinary fields. At the conference, Professor Pan Jianji from Xiamen Humanity Hospital introduced the overview of the Phase Ⅰ clinical trial of Neuboron's innovative BNCT drug-device products, which initially showed good clinical efficacy. As a cutting-edge emerging technology, the future of BNCT urgently needs more attention and support. It is expected that more experts, young scholars, and doctors will join in to jointly promote the development of the BNCT cause.
